SCHEMBL6890901

SCHEMBL6890901

Cc1cccc(C)c1OC(=O)OC(C)I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATM Q13315 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SCN4A P35499 7/20 0.37
LMNA P02545 2/20 0.37
SCN1A P35498 2/20 0.37
SCN5A Q14524 2/20 0.37
SCN9A Q15858 2/20 0.37
TSHR P16473 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
NFKB1 P19838 2/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31470807 0.85 L3MBTL1 (0.50) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6893753 0.82 MEN1 (0.32) L3MBTL1KDM4EALDH1A1HPGDMEN1
SCHEMBL6892954 0.81 TDP1 (0.44) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL8764787 0.80 L3MBTL1 (0.55) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL25257372 0.79 L3MBTL1 (0.55) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL10959076 0.77 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6890520 0.75 LMNA (0.57) SMN1; SMN2ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6895672 0.74 ALDH1A1 (0.42) L3MBTL1ALDH1A1HPGDHSD17B10ATM
SCHEMBL24394204 0.73 L3MBTL1 (0.62) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6894762 0.73 L3MBTL1 (0.49) L3MBTL1SMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 L3MBTL1 2671/4885SMN1; SMN2 2954/4885KDM4E 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.